Paper Information

Journal:   ACTA MEDICA IRANICA   2003 , Volume 41 , Number 1; Page(s) 66 To 68.
 
Paper: 

PREVALENCE OF INHIBITORS IN A POPULATION OF 1280 HEMOPHILIA A PATIENTS IN IRAN

 
 
Author(s):  SHARIFIAN H.*, HOSEINI M., SAFAI R., TUGEH GH., EHSANI A.H., LAK M., JAZEBI M.
 
* Tehran, Iran
 
Abstract: 
Development of inhibitor to factor VIII is the most serious complication of hemophilia therapy. To determine the prevalence of inhibitors in Iran hemophilia A patients exposed to blood products, 1280 hemophilia A patients (age range 9 months-84 years) were evaluated. All patients received several blood products such as fresh frozen plasma (FFP), cryoprecipitate, factor VIII. 635 of 1280 patients (49.6%), 277 patients (21.6%) and 368 patients (28.8%) had sever, moderate and mild disease, respectively. 184 of 1280 patients (14.4%) developed inhibitor. The prevalence of inhibitor for severe, moderate and mild in hemophilia A patients was 22.8%, 9.4%, 3.5% respectively. 41 patients (22.2%) and 1, patients (77.8%) were high responder and low responder respectively. Among 184 patients with inhibitor, 67 patients (36.4%) had blood group O and for B, A, AB blood groups, number of patients with inhibitor was 55 (29.9%), 50 (27.2%) 12 (6.5%) respectively and 153 patients (83.1%) had Rh blood group.
 
Keyword(s): HEMOPHILIA A, INHIBITORS, PREVALENCE, FACTOR VIII
 
References: 
 
  pdf-File tarjomyar Yearly Visit 85
 
Latest on Blog
Enter SID Blog